BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tambotatug pelitecan readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tambotatug pelitecan\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07208773-2817@assetmemo.bio
DTSTAMP:20261121T005942Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Tambotatug pelitecan: Phase 1/2 readout est. (NCT07208773)
DESCRIPTION:Tambotatug pelitecan\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors\
 nEstimated primary completion: January 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07208773
URL:https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06241846-2817@assetmemo.bio
DTSTAMP:20261121T005942Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Tambotatug pelitecan: Phase 2 readout est. (NCT06241846)
DESCRIPTION:Tambotatug pelitecan\, phase 2.\nStudy: A Phase II Study to Eva
 luate the Safety\, Efficacy\, and Pharmacokinetics of YL201 in Patients Wi
 th mCRPC\nEstimated primary completion: February 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06241846
URL:https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05434234-2817@assetmemo.bio
DTSTAMP:20261121T005942Z
DTSTART;VALUE=DATE:20270406
DTEND;VALUE=DATE:20270407
SUMMARY:Tambotatug pelitecan: Phase 1/2 readout est. (NCT05434234)
DESCRIPTION:Tambotatug pelitecan\, phase 1/2.\nStudy: A Study of YL201 in P
 atients With Advanced Solid Tumors\nEstimated primary completion: 6 April 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/tambotatug-peli
 tecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05434234
URL:https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06394414-2817@assetmemo.bio
DTSTAMP:20261121T005942Z
DTSTART;VALUE=DATE:20270429
DTEND;VALUE=DATE:20270430
SUMMARY:Tambotatug pelitecan: Phase 1 readout est. (NCT06394414)
DESCRIPTION:Tambotatug pelitecan\, phase 1.\nStudy: A Phase 1 Study to Eval
 uate the Safety\, Efficacy\, and Pharmacokinetics of YL201 in Advanced Sol
 id Tumors\nEstimated primary completion: 29 April 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06394414
URL:https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06612151-2817@assetmemo.bio
DTSTAMP:20261121T005942Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Tambotatug pelitecan: Phase 3 readout est. (NCT06612151)
DESCRIPTION:Tambotatug pelitecan\, phase 3\, Small Cell Lung Cancer.\nStudy
 : A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer (TAISHAN-3
 02)\nEstimated primary completion: 1 December 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06612151
URL:https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06629597-2817@assetmemo.bio
DTSTAMP:20261121T005942Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Tambotatug pelitecan: Phase 3 readout est. (NCT06629597)
DESCRIPTION:Tambotatug pelitecan\, phase 3\, Nasopharyngeal Carcinoma.\nStu
 dy: A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal C
 arcinoma (TAISHAN-301)\nEstimated primary completion: 1 December 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/tambotatug-pelitecan#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0662959
 7
URL:https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07258979-2817@assetmemo.bio
DTSTAMP:20261121T005942Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Tambotatug pelitecan: Phase 1/2 readout est. (NCT07258979)
DESCRIPTION:Tambotatug pelitecan\, phase 1/2\, Nasopharyngeal Carcinoma.\nS
 tudy: A Study of YL201 in Combination With Toripalimab and With or Without
  Cisplatin in Nasopharyngeal Carcinoma.\nEstimated primary completion: Feb
 ruary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tambotatu
 g-pelitecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07258979
URL:https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07487896-2817@assetmemo.bio
DTSTAMP:20261121T005942Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Tambotatug pelitecan: Phase 3 readout est. (NCT07487896)
DESCRIPTION:Tambotatug pelitecan\, phase 3\, Esophageal Squamous Cell Carci
 noma.\nStudy: A Study of YL201 Versus Investigator's Choice of Chemotherap
 y in Participants With Locally Advanced or Metastatic Esophageal Squamous 
 Cell Carcinoma After Failure of First-Line Therapy\nEstimated primary comp
 letion: 30 April 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/tambotatug-pelitecan#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07487896
URL:https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407933-2817@assetmemo.bio
DTSTAMP:20261121T005942Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Tambotatug pelitecan: Phase 1/2 readout est. (NCT07407933)
DESCRIPTION:Tambotatug pelitecan\, phase 1/2\, Small Cell Lung Cancer.\nStu
 dy: A Study of YL201 in Combination With Other Anti-Cancer Therapies in Pa
 tients With Advanced Solid Tumors\nEstimated primary completion: November 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/tambotatug-peli
 tecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07407933
URL:https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07803783-2817@assetmemo.bio
DTSTAMP:20261121T005942Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Tambotatug pelitecan: Phase 3 readout est. (NCT07803783)
DESCRIPTION:Tambotatug pelitecan\, phase 3\, Pancreatic Ductal Adenocarcino
 ma.\nStudy: A Study to Compare the Efficacy and Safety of YL201 With Stand
 ard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failu
 re of Gemcitabine-Based Systemic Chemotherapy\nEstimated primary completio
 n: January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tamb
 otatug-pelitecan#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07803783
URL:https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07739758-2817@assetmemo.bio
DTSTAMP:20261121T005942Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Tambotatug pelitecan: Phase 3 readout est. (NCT07739758)
DESCRIPTION:Tambotatug pelitecan\, phase 3\, Small Cell Lung Cancer.\nStudy
 : A Study of YL201 in Combination With Serplulimab in Participants With Tr
 eatment-naïve Extensive-stage Small Cell Lung Cancer\nEstimated primary c
 ompletion: June 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /tambotatug-pelitecan#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07739758
URL:https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06898957-2817@assetmemo.bio
DTSTAMP:20261121T005942Z
DTSTART;VALUE=DATE:20310623
DTEND;VALUE=DATE:20310624
SUMMARY:Tambotatug pelitecan: Phase 1 readout est. (NCT06898957)
DESCRIPTION:Tambotatug pelitecan\, phase 1\, Small Cell Lung Cancer.\nStudy
 : Study of Tarlatamab in Combination With YL201 With or Without Anti-progr
 ammed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Sma
 ll Cell Lung Cancer (SCLC)\nEstimated primary completion: 23 June 2031. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/tambotatug-pelitecan#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT068989
 57
URL:https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
